Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC).
H. A. Wakelee
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
S. E. Dahlberg
No relevant relationships to disclose
S. M. Keller
No relevant relationships to disclose
D. R. Gandara
Consultant or Advisory Role - Genentech
S. L. Graziano
Research Funding - Genentech
N. B. Leighl
No relevant relationships to disclose
A. A. Adjei
No relevant relationships to disclose
J. H. Schiller
Consultant or Advisory Role - Roche/Genentech
Research Funding - Genentech